Clinical Trial Update: Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicates the MRX34 microRNA liposomal injection study in melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MRX34

Snippet

Sponsor: Mirna Therapeutics, Inc. | Conditions: Melanoma | Phase 1, Phase 2 | Status: WITHDRAWN